AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward. We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and drive inventive Life Sciences start-ups to success. We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.
Calida Therapeutics
Seed Round in 2023
Calida Therapeutics operates as a biotechnology company. Calida Therapeutics develops monoclonal antibodies to treat and prevent thrombo-inflammatory disorders.
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development programs are focused on the treatment of melanoma, is developing a pipeline of molecules that target the eukaryotic translation Initiation Factor-4A. (eIF4A). This target is active in a wide range of solid and hematologic cancers, including melanoma, and is linked to resistance to many current treatments. Ribonexus's goal is to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who have become resistant to them.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.
Thabor Therapeutics develops innovative treatments for mucosal inflammatory diseases. They concentrated on inhibiting a new target to treat human mucosal inflammatory disorders. They also enable healthcare providers to cure their patients.
ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases. Our team has a strong background on drug discovery and microRNAs involvement in neuromuscular diseases. We are supported by world-renowned scientific and clinical advisors that will facilitate the successful development of our products.
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
Alderaan Biotechnology is a Biotechnology company develops antibodies targeting new and original targets in immuno-oncology, expressed by NK cells in particular.
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair.
Urania Therapeutics company is developing a unique SBDD platform for the generation of new readthrough compounds with high potential in cancer and monogenic disorders.
Yukin Therapeutics is a French biotechnology company. The company focuses on the development of new therapeutic molecules, entitled kinase inhibitors, specifically targeting a protein involved in the development of several types of cancer: the NIK protein (NF-κB inducing kinase). Yukin Therapeutics led studies that demonstrated proof of concept in animal models and is now actively seeking to identify a first drug candidate to launch a clinical trial in oncology.
Tridek is a developer of immunomodulatory products intended for moderating overactive responses without blockade. The company's product is a peptide which maintains cluster of truncated CD31 to the membrane for a diversity of auto-immune and inflammatory disorders, enabling medical companies to treat their patients with better drugs and give them a better life.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that can potentially restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases. The company is focusing on biologically validated pathways, such as Transforming Growth Factor β and Hepatocyte Growth Factor, and leveraging specialized capabilities in organ-specific small molecules and high-affinity antibodies. With a diversified clinical pipeline across multiple fibrotic conditions, end-to-end research and development expertise, a successful business development track record, and a robust investor base.
Alderaan Biotechnology is a Biotechnology company develops antibodies targeting new and original targets in immuno-oncology, expressed by NK cells in particular.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.